Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?

Abstract

The most common genetic disorder in Philadelphia negative chronic myeloproliferative neoplasms is the JAK2-V617F mutation. In the present study, we aimed to determine risk factors for thrombosis in patients with essential thrombocytosis and polycythemia vera. We screened the medical records of 101 patients. Risk factors which may predict thrombosis were recorded. Venous thrombosis (VT) before diagnosis was significantly higher in JAK2 positive patients. VT after diagnosis was similar in JAK2 positive and negative groups, and was significantly higher in elderly patients. Treatment places importance on the JAK2 mutation under unmodifiable cardiovascular risk factors such as advanced age after diagnosis.

Myeloproliferative Neoplasms, an Acquired Thrombophilic State: JAK2 and Beyond

“…Although the current Turkish study [1] had a relatively small sample size, it revealed some unusual findings. The JAK2 mutation's presence modulated thrombotic risk prior to diagnosis, but not subsequently, suggesting a neutralization of its effect by effective therapy.…”

“…The JAK2 mutation, if present, is a well-established risk factor for thrombosis in ET [3,4], a finding has also confirmed in the publication by Uyanik et al [1]. The V617F allele burden is known to be associated with acquired activated protein C resistance, low free PS and increased levels of soluble markers of endothelial and platelet activation including elevated tissue factor [5][6][7].…”

“…In the current issue of IJHBT, Uyanik et al [1] present data from 101 patients with essential thrombocythemia (ET) and polycythemia vera (PV) with reference to the development of thrombotic complications. The paper provides interesting insights into this fascinating, and clinically highly relevant aspect of the Ph-negative myeloproliferative neoplasms (MPN).…”

Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia

“…Several studies have shown that JAK2V617F may increase the likelihood of thrombotic events in ET patients. Therefore, it has been included in prognostic models and its presence may guide treatment decisions 36,37 . Subsequent meta analyses and systematic reviews of the literature showed that among patients with ET, the risk of thrombosis is about twice as high in those with the JAK2V617F mutation compared to those without.…”

“…Therefore, it has been included in prognostic models and its presence may guide treatment decisions. 36 , 37 Subsequent meta analyses and systematic reviews of the literature showed that among patients with ET, the risk of thrombosis is about twice as high in those with the JAK2V617F mutation compared to those without. Based on this data, patients with CALR mutation have better prognosis with lower incidence of thrombotic events relative to patients bearing JAK2V617F mutation associated with an increased risk of thrombosis.…”